Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials

 
• By Bridget Silverman
ODAC meeting
ODAC members gathered in person for the 12 April meeting, but the public, press and open public hearing speakers participated virtually. • Source: screenshot

More from US FDA Performance Tracker

More from Regulatory Trackers